Literature DB >> 9783546

Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood.

A Rogers1, R Eastell.   

Abstract

Estrogen replacement therapy (ERT) is known to prevent bone loss following the menopause, but the mechanism for this is unclear. Estrogen may suppress the secretion of certain bone-resorbing cytokines. The aim of this study was to assess the effect of ERT on the levels of cytokines measured in peripheral blood. We measured cytokines in 10 postmenopausal women (ages 56-59, 3-9 years since menopause) treated with ERT and 10 age-matched (54-59 years, 4-10 years since menopause) untreated women as controls. Samples of blood were taken and used for mononuclear cell cultures, whole blood (WB) cultures, and the separation of serum. The cultures were treated with lipopolysaccharide (LPS; 500 ng/ml) and hydrocortisone (10(-6) M). The conditioned medium from cultures and the serum were then assayed for interleukin-6 (IL-6), IL-1alpha IL-1beta, IL-1 IL-1ra, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony stimulating factor (GM-CSF) by enzyme-linked immunosorbent assay. M-CSF and the soluble cytokine receptors soluble IL-6 receptor (sIL-6r) and soluble TNF receptor type 1 (sTNFr1) were also measured in serum and M-CSF in stimulated WB cultures. Measurements were corrected for mononuclear cell count. We also measured serum bone-specific alkaline phosphatase (ibAP) in all subjects. We found that LPS stimulated secretion of all cytokines both in WB and isolated cell cultures, and that this was attenuated by hydrocortisone. A significantly higher ratio of IL-1beta/IL-1ra (p = 0.02) in LPS stimulated WB cultures was seen in the untreated women. Levels of IL-1beta and IL-1alpha measured in WB cultures were lower and IL-1ra was higher in the ERT-treated group but these results were not significant. BAP was higher in the untreated group (p = 0.005) and correlated with IL-alpha/IL-1ra in the whole group (r = 0.49, p = 0.03). Results of other measurements showed no significant differences between groups. We conclude that estrogen may prevent bone loss following the menopause by altering the balance between IL-1beta and IL-1ra.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783546     DOI: 10.1359/jbmr.1998.13.10.1577

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.

Authors:  Yuhao Gao; Francesco Grassi; Michaela Robbie Ryan; Masakazu Terauchi; Karen Page; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

2.  Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women.

Authors:  Satish Bharadwaj; Tezus A G Naidu; Guru V Betageri; Nemani V Prasadarao; A Satyanarayan Naidu
Journal:  Inflamm Res       Date:  2010-05-15       Impact factor: 4.575

3.  Estrogen prevents bone loss through transforming growth factor beta signaling in T cells.

Authors:  Yuhao Gao; Wei-Ping Qian; Kimberly Dark; Gianluca Toraldo; Angela S P Lin; Robert E Guldberg; Richard A Flavell; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-05       Impact factor: 11.205

4.  Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women.

Authors:  Morgan A Marks; Patti E Gravitt; Robert D Burk; Yevgeniy Studentsov; Homayoon Farzadegan; Sabra L Klein
Journal:  Clin Vaccine Immunol       Date:  2010-02-03

5.  Estrogen decreases tight junction protein ZO-1 expression in human primary gut tissues.

Authors:  Zejun Zhou; Lumin Zhang; Miao Ding; Zhenwu Luo; Shao Yuan; Meena B Bansal; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2017-09-01       Impact factor: 3.969

6.  Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal women.

Authors:  Natalie E Silverman; Barbara J Nicklas; Alice S Ryan
Journal:  Calcif Tissue Int       Date:  2009-03-11       Impact factor: 4.333

7.  Tumor necrosis factor alpha (TNF-α) and estrogen hormone in osteoarthritic female patients.

Authors:  Pradeep Sharma; Neelima Singh; Vinod Singh; Sanjeev Singh; Harsh Vardhan Singh; Sameer Gupta
Journal:  Indian J Clin Biochem       Date:  2006-03

8.  The effects of 6-gingerol on proliferation, differentiation, and maturation of osteoblast-like MG-63 cells.

Authors:  J Z Fan; X Yang; Z G Bi
Journal:  Braz J Med Biol Res       Date:  2015-04-28       Impact factor: 2.590

9.  Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels.

Authors:  Lowell T Ku; Cicek Gercel-Taylor; Steven T Nakajima; Douglas D Taylor
Journal:  Immun Ageing       Date:  2009-03-05       Impact factor: 6.400

10.  Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer.

Authors:  C Dabrosin; K Palmer; J Gauldie
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.